Generation of induced pluripotent stem cells from patients with multiple myeloma
MetadataShow full item record
CitationYılmaz Başaran, İ., & Karaöz, E. (2021). Generation of Induced Pluripotent Stem Cells from Patients with Multiple Myeloma. Turkish journal of haematology : official journal of Turkish Society of Haematology, 10.4274/tjh.galenos.2021.2020.0682. Advance online publication. https://doi.org/10.4274/tjh.galenos.2021.2020.0682
Yamanaka and Takahashi made a discovery in the world of life science by transforming mouse somatic fibroblasts into pluripotent cells as a result of transferring 4 gene sets (Sox2-Oct4- Klf4&c-Myc) in 2006 (1). Since that day, induced pluripotent stem cells (iPSCs) are considered to be one of the main sources for regenerative medicine; like embryonic stem cells (ESCs). Because of their pluripotent features, both cell types are building blocks of regenerative medicine. There are no ethical limitations and immunological problems for iPSCs when compared to ESCs (2). Additionally, iPSCs with disease genotypes have been used for human disease modeling (3).